news: southern star research to present australia’s biotech benefits at oct, la jolla

News: Southern Star Research to present Australia’s biotech benefits at OCT, La Jolla

Southern Star Research, an Australian and Asia-Pacific CRO specializing in clinical trial acceleration with FDA data compliance, is at OCT La Jolla this week to discuss the benefits of conducting trials in Australia.

Book a meeting with Southern Star Research here, or meet the team at #Booth 61

Southern Star Research, Director Corporate Development, Chris Stellatos said Australia has positioned itself as the most attractive clinical trial destination.

“Supportive rebates, scientific excellence, and rapid approval processes including no requirement for an IND make Australia the stand-out location to conduct clinical trials.”

“The Australian Government has made all the right adjustments to support the sector and the winners are biotechs.”

“The attractive benefits apply to Australian and overseas biotechs, and are designed to launch biotech clinical programs quickly and cost-effectively.”

Benefits of conducting trials in Australia include:

  • A streamlined approvals process, resulting in as short as a 4-8 week timeline from submission to site initiation
  • A favourable regulatory framework – no need to lodge an Investigational New Drug (IND) application
  • Generous cost savings and tax incentives – potentially up to 60% less than the US, EU and other major jurisdictions
  • World-class facilities, medical infrastructure and talent, resulting in data accepted by the FDA, EMA and other regulators

The streamlined clinical trial approvals process in Australia means a study can be approved in less than 8 weeks and avoid an IND.

The process timeline includes:

  • The Human Research Ethics Committee (HREC) approval process takes 4–6 weeks on average. Site governance documents are submitted concurrently and typically take 6-8 weeks.
  • Clinical Trial Notification (CTN) is the final step in the approval process.
  • Confirmation from the TGA is usually received within 2–3 days, allowing the sponsor to formally commence the study.

About Southern Star Research

Founded in 2010 and headquartered in Sydney, Australia, Southern Star Research is a full-service CRO helping sponsors to navigate the complexities of bringing new medical products to market. Since commencing operations in Sydney, we have grown to become an international team of specialists, managing studies across the globe.

With a focus on the biotechnology and medical device industries, we offer flexible and bespoke solutions that meet the unique needs of each project. While we have experience across all study phases, we are early phase specialists (Phase 1 and 2) with particular expertise in designing and managing clinical trials that ensure your asset is ready for larger Phase 3 and 4 studies, licensing, partnering and acquisition.

We believe a customer-first approach, transparent relationships and a proactive team of experts are the best path to achieving successful commercial outcomes for our clients.